The purpose of the study is to test whether increased saturated fat intake results in increased levels of larger LDL and HDL particles in individuals with LDL Pattern B.
Increased saturated fat intake is known to elevate plasma levels of both low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), however, less is know regarding the effect of saturated fat on lipoprotein subclasses. We previously showed that, in the context of a reduced carbohydrate diet, saturated fat induced increases in LDL cholesterol were apparently due to increases in large, more buoyant LDL without increases in small, dense LDL. This finding was supported by a previous dietary intervention study showing a correlation between saturated fat intake and large LDL. In both cases, this increase in large LDL was correlated with an increase in large HDL. In this study, we will test the following specific hypotheses regarding changes in plasma lipoproteins induced by a diet high in myristic acid and other saturated fats derived primarily from dairy sources in individuals with LDL subclass pattern B: 1) there will be a coordinate increase in levels of large HDL particles that are considered anti-atherogenic and large LDL particles that are less strongly associated with increased CVD risk than smaller LDL; 2) this change in lipoprotein profile will result in a higher proportion of pattern B individuals converting to LDL subclass pattern A (predominance of larger LDL); and 3) the coordinate increase in large HDL and LDL is due to a common underlying pathway. The latter hypothesis will be addressed by assaying cholesterol ester transfer protein (CETP), hepatic lipase (HL), and lipoprotein lipase (LPL).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Enrollment
53
Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
Cholesterol Research Center
Berkeley, California, United States
Large LDL (LDL I + 2a) (mg/dl)
Time frame: 3 wk, 6 wk
Large HDL (HDL2b) (mg/dl)
Time frame: 3 wk, 6 wk
LDL peak particle size
Time frame: 3 wk, 6 wk
Triglycerides (mg/dl)
Time frame: 3 wk, 6 wk
Total Cholesterol (mg/dl)
Time frame: 3 wk, 6 wk
LDL cholesterol (mg/dl)
Time frame: 3 wk, 6 wk
HDL cholesterol (mg/dl)
Time frame: 3 wk, 6 wk
Apolipoprotein AI (mg/dl)
Time frame: 3 wk, 6 wk
Apolipoprotein B (mg/dl)
Time frame: 3 wk, 6 wk
Medium LDL (LDL2b) (mg/dl)
Time frame: 3 wk, 6 wk
Small LDL (LDL3a) (mg/dl)
Time frame: 3 wk, 6 wk
Hepatic Lipase Activity
Time frame: 3 wk, 6 wk
Lipoprotein Lipase Activity
Time frame: 3 wk, 6 wk
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Cholesteryl Ester Transfer Protein Activity
Time frame: 3 wk, 6 wk
Very Small LDL (LDL3b, 4a, 4b) (mg/dl)
Time frame: 3 wk, 6 wk